Pdt Partners, LLC Intercept Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.21 - $19.7 $952,917 - $1.54 Million	-78,044 Reduced 56.72%	59,552 $831,000
Q2 2022 Aug 15, 2022	BUY	$11.23 - $19.59 $38,339 - $66,880	3,414 Added 2.54%	137,596 $1.9 Million
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $1.46 Million - $1.95 Million	109,525 Added 444.19%	134,182 $2.18 Million
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $352,101 - $481,551	24,657 New	24,657 $402,000
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $1.49 Million - $2.34 Million	-114,515 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$15.46 - $24.5 $60,649 - $96,113	3,923 Added 3.55%	114,515 $2.29 Million
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $115,748 - $226,047	5,988 Added 5.72%	110,592 $2.55 Million
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $5,924 - $10,277	-242 Reduced 0.23%	104,604 $2.58 Million
Q3 2020 Nov 16, 2020	BUY	$39.09 - $53.44 $4.1 Million - $5.6 Million	104,846 New	104,846 $4.35 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $4.63 Million - $6.82 Million	-53,932 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$88.49 - $127.55 $2.32 Million - $3.35 Million	26,260 Added 94.9%	53,932 $6.82 Million
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $1.66 Million - $2.37 Million	27,672 New	27,672 $2.32 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.